Skip to content

US · KIDS · MEDICAL - DEVICES

OrthoPediatrics Corp. (KIDS) intrinsic value and stock valuation

$31.74as of 2026-11-21 · Mkt cap 573.03M

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

OrthoPediatrics Corp. DCF and intrinsic value

InvestorsCraft values KIDS with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from KIDS’s statements →

OrthoPediatrics Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Warsaw, IN 46582 orthopediatrics.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$236.4M+27.2% 5y CAGRd
20142025
Net income
-$-39.65M
20142025
Free cash flow
-$-15.96M
20142025
Total equity
$346.6M+8.1% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$236.4M$204.7M$148.7M$122.3M$98.1M
Operating income-$-29M-$-29.52M-$-26.75M-$-25.4M-$-18.02M
Net income-$-39.65M-$-37.82M-$-20.97M$1.26M-$-16.26M
EPSd-$-1.69M-$-1.64M-$-924.6K$60.1K-$-843.8K
Operating cash flow-$-4.85M-$-27.05M-$-27.05M-$-21.77M-$-13.06M
Capital expenditure-$-11.11M-$-14.26M-$-18.98M-$-10.03M-$-16.01M
Free cash flow-$-15.96M-$-41.31M-$-46.03M-$-31.8M-$-29.07M
Total assets$508.6M$473.2M$438.8M$427.7M$308.4M
Total debt$100M$80.9M$10.1M$910K$28.5M
Net debt$80.4M$37.1M-$-21M-$-8.08M$19.5M
Total equity$346.6M$354.6M$377M$378.7M$225.4M
Cash and short-term investments$60.9M$68.8M$80.3M$118.3M$54.9M
Income statement
20252024202320222021
Revenue$236.4M$204.7M$148.7M$122.3M$98.1M
Cost of revenue$63.7M$56.1M$37.5M$31.6M$24.7M
Gross profit$172.7M$148.6M$111.3M$90.7M$73.4M
Research and development expenses$9.1M$11M$10.9M$8.45M$5.54M
Selling, general and administrative expenses$192.6M$167.1M$126.1M$104M$85.7M
Other expenses$0.00$0.00$980K$3.61M$150K
Operating expenses$201.7M$178.1M$138M$116.1M$91.4M
Cost and expenses$265.4M$234.3M$175.5M$147.7M$116.1M
Interest income$0.00$0.00$200K$0.00$0.00
Interest expense$6M$2.62M$0.00$2.42M$2.25M
Depreciation and amortization$21.3M$19.1M$17.4M$13.1M$10.7M
Ebitda-$-11.94M-$-20.23M-$-8.38M-$-8.69M-$-7.19M
Operating income-$-29M-$-29.52M-$-26.75M-$-25.4M-$-18.02M
Total other income/expenses, net-$-10.19M-$-12.41M$5.44M$21.7M$640K
Income before tax-$-39.19M-$-41.93M-$-21.31M-$-3.69M-$-17.39M
Income tax expense$460K-$-4.11M-$-340K-$-4.95M-$-1.13M
Net income-$-39.65M-$-37.82M-$-20.97M$1.26M-$-16.26M
Weighted average shares outstanding$23.5M$23.1M$22.7M$20.7M$19.3M
Weighted average diluted shares outstanding$23.5M$23.1M$22.7M$21M$19.3M
Balance sheet
20252024202320222021
Cash and short-term investments$60.9M$68.8M$80.3M$118.3M$54.9M
Net receivables$53.8M$42.4M$34.6M$24.8M$17.9M
Inventory$133.8M$117M$105.9M$78.2M$57.6M
Total current assets$256.4M$237.2M$226.5M$226.7M$133.7M
Property, plant and equipment, net$49.6M$58.8M$41.1M$34.3M$28.5M
Goodwill and intangible assets$187M$175M$168.3M$166.7M$142.1M
Long-term investments$0.00$2.18M$1.85M$189.5M$0.00
Total non-current assets$252.2M$236M$212.3M$201M$174.8M
Total assets$508.6M$473.2M$438.8M$427.7M$308.4M
Accounts payable$18.8M$8.91M$12.7M$11.2M$9.32M
Short-term debt$170K$2.28M$150K$140K$13M
Deferred revenue$0.00$0.00$0.00$5.95M$0.00
Total current liabilities$46.2M$34M$41.7M$30.9M$29.7M
Long-term debt$99.8M$78.6M$9.91M$760K$15.5M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$115.8M$84.7M$20.1M$18.2M$53.3M
Capital lease obligations$0.00$7.78M$0.00$0.00$290K
Total liabilities$162M$118.6M$61.7M$49.1M$83M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-275.21M-$-235.56M-$-197.74M-$-176.77M-$-178.03M
Accumulated other comprehensive income (loss)-$-520K-$-10.77M-$-5.53M-$-5.4M$8.49M
Total equity$346.6M$354.6M$377M$378.7M$225.4M
Total investments$41.3M$27.2M$51.1M$298.8M$45.9M
Total debt$100M$80.9M$10.1M$910K$28.5M
Net debt$80.4M$37.1M-$-21M-$-8.08M$19.5M
Cash flow statement
20252024202320222021
Net income-$-39.65M-$-37.82M-$-20.97M$1.26M-$-16.26M
Depreciation and amortization$21.1M$19.1M$17.4M$13.1M$10.7M
Stock-based compensation$17.8M$13.6M$10.5M$6.68M$5.84M
Change in working capital-$-10.79M-$-22.93M-$-32.2M-$-17.76M-$-12.55M
Accounts receivable-$-9.37M-$-4.75M-$-9.72M-$-3.98M-$-470K
Inventory-$-8.47M-$-13.2M-$-26.28M-$-16.94M-$-5.05M
Accounts payable$8.17M-$-4.28M$1.49M-$-210K-$-570K
Net cash provided by operating activities-$-4.85M-$-27.05M-$-27.05M-$-21.77M-$-13.06M
Investments in property, plant and equipment-$-11.11M-$-14.26M-$-16.88M-$-10.03M-$-16.01M
Acquisitions, net-$-15.5M-$-20.23M-$-3.64M-$-40.09M$0.00
Net cash used for investing activities-$-43.63M-$-13.16M$41.7M-$-113.37M-$-7.41M
Common stock issued$0.00$0.00$20K$139.3M$140K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$24M$53.1M$7.3M$136M$10K
Net change in cash-$-24.16M$12.8M$22.6M$1.46M-$-21.13M
Cash at end of period$21.6M$45.8M$33M$10.5M$9.01M
Operating cash flow-$-4.85M-$-27.05M-$-27.05M-$-21.77M-$-13.06M
Capital expenditure-$-11.11M-$-14.26M-$-18.98M-$-10.03M-$-16.01M
Free cash flow-$-15.96M-$-41.31M-$-46.03M-$-31.8M-$-29.07M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About OrthoPediatrics Corp.

        OrthoPediatrics Corp. is a medical technology firm dedicated to the design, development, and global commercialization of specialized implants and devices. These products are meticulously crafted to be anatomically appropriate for treating children affected by orthopedic conditions across the United States and internationally. The company's diverse offerings span products for trauma and deformity correction, surgical systems for spinal deformities such as scoliosis, and solutions for sports medicine, among others. Their comprehensive product line features items like PediLoc, PediPlates, various cannulated screws, the PediFlex and PediNail systems, PediLoc tibia, advanced anterior cruciate ligament reconstruction systems, specialized locking cannulated blades and proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, the Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and the ApiFix Mid-C system. OrthoPediatrics Corp. primarily serves the pediatric orthopedic market, directly assisting pediatric orthopedic surgeons and caregivers. The company was founded in 2006 and maintains its headquarters in Warsaw, Indiana.

        CEO
        David R. Bailey
        Employees
        602
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of OrthoPediatrics Corp. (KIDS)?

        OrthoPediatrics Corp. (KIDS) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KIDS undervalued?

        KIDS trades at a price of $31.74 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.